Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium LU 177-edotreotide

A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:177Lu-DOTA-Tyr3-octreotide
lutetium Lu 177 DOTA-tyr3-octreotide
lutetium Lu 177-DOTA-edotreotide
Abbreviation:[177LuDOTA]-TOC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search